Guardant CTO granted 23,856 restricted stock units

Guardant Health, Inc. Chief Technology Officer Darya Chudova reported a grant of 23,856 restricted stock units.

Rhea-AI Filing Summary

Guardant Health, Inc. Chief Technology Officer Darya Chudova reported a grant of 23,856 restricted stock units. The award was granted on March 11, 2026 and will convert into an equal number of common shares as it vests. According to the vesting schedule, 33% of the units will vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, her reported direct holdings in this award total 23,856 restricted stock units.

Insider Trade Summary

Grant/Award: 23,856 shares

Grant/Award 1 txn

Insider Chudova Darya

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	23,856	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 23,856 contracts (Direct)

Footnotes (2)

1. F1. This represents a restricted stock unit award granted on March 11, 2026 that vests over a three-year period. 33% of the shares subject to such award will vest on April 1, 2027 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
2. F2. Not applicable for Restricted Stock Units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardant Health (GH) CTO Darya Chudova report?

Guardant Health CTO Darya Chudova reported receiving 23,856 restricted stock units as a compensation award. The grant was made on March 11, 2026 and represents restricted stock units that will settle into common shares as they vest over a multi-year schedule.

How many restricted stock units were granted to the Guardant Health CTO?

Darya Chudova received a grant of 23,856 restricted stock units. Each unit represents a right to receive one share of Guardant Health common stock, subject to time-based vesting conditions set out in the award’s three-year vesting schedule disclosed in the filing footnotes.

What is the vesting schedule for Darya Chudova’s 23,856 RSUs at Guardant Health (GH)?

The 23,856 restricted stock units vest over three years. Thirty‑three percent of the units vest on April 1, 2027, while the remaining 67% vest in equal quarterly installments over the subsequent two years, contingent on continued service or other applicable award terms.

Are Darya Chudova’s newly granted Guardant Health RSUs an open-market purchase?

No, the filing describes the transaction as a grant or award acquisition of restricted stock units, not an open-market purchase. The Form 4 shows transaction code A, indicating a compensation-related award rather than shares bought on the open market.

How many Guardant Health restricted stock units does Darya Chudova hold after this Form 4?

Following the reported transaction, Darya Chudova’s holdings from this award total 23,856 restricted stock units. These units are reported as directly owned and will convert into common stock only as they satisfy the time-based vesting schedule described in the filing footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 08:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chudova Darya

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/11/2026		A		23,856		(1)	(2)	Common Stock	23,856	$0	23,856	D

Explanation of Responses:

1. This represents a restricted stock unit award granted on March 11, 2026 that vests over a three-year period. 33% of the shares subject to such award will vest on April 1, 2027 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Darya Chudova	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.